查找临床试验
已按「多发性骨髓瘤」检索，对应国际通用词 multiple myeloma
共找到 175 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 23:03，每 5 分钟自动同步Universal CAR-T Cell Therapy for MM
China
年龄 18 Years – 不限
Bioray Laboratories
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
United States、Argentina、Australia、Brazil、China 等 12 国
年龄 18 Years – 不限
GlaxoSmithKline
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma
China
年龄 18 Years – 不限
UCARsgen Biotech Limited
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
United States、Australia、China、Georgia、Serbia
年龄 18 Years – 不限
Shanghai Henlius Biotech
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 不限
Pfizer
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
United States、China
年龄 18 Years – 不限
Jiangsu Simcere Pharmaceutical Co., Ltd.
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
China
年龄 18 Years – 不限
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.
China
年龄 18 Years – 不限
Beijing Mabworks Biotech Co., Ltd.
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
China
年龄 65 Years – 不限
The First Affiliated Hospital with Nanjing Medical University
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
China
年龄 19 Years – 75 Years
Anhui Provincial Hospital
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
China
年龄 18 Years – 80 Years
Hangzhou Sumgen Biotech Co., Ltd.
68Ga-BCMA PET/CT in Multiple Myeloma
China
年龄 18 Years – 80 Years
Peking University First Hospital